1
|
Chekhlyaeva TS, Erokhov DV, Andrievskaya IY, Zherdeva PE, Tikhonova NT. [Genetic diversity of the mumps viruses (Paramyxoviridae: Orthorubulavirus: Mumps orthorubulavirus): an overview]. Vopr Virusol 2022; 67:95-106. [PMID: 35521982 DOI: 10.36233/0507-4088-98] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 05/05/2022] [Indexed: 11/05/2022]
Abstract
Mumps is an infectious disease controlled by specific vaccine prophylaxis. To date, its social and epidemiological significance remains high. This is evidenced by the process of developing and implementing into the health care practices of many countries a set of measures for surveillance of mumps. In the Russian Federation, the National Program «Elimination of measles and rubella and achievement of sporadic morbidity with epidemic mumps in the Russian Federation (2021-2025)» and the national plan for its implementation were adopted in 2021. The basis for the adoption of these documents was the development of the domestic trivalent vaccine for the prevention of measles, rubella and mumps, Vaktrivir, and the start of its clinical application. The availability of this vaccine will make the epidemiological surveillance of mumps to be a part of the existing system of appropriate measures for measles and rubella. The fulfillment of this set of tasks involves the study of the molecular epidemiology of the mumps virus (MuV) with possible subsequent implementation of its methodology into the surveillance actions. In this connection, this work was aimed at presenting the data on global genetic diversity of MuV as well as its genotyping methods in a systematized form. The analysis of MuV global genetic diversity in different years will be the starting point in the subsequent development of approach to monitoring virus strains circulating in the Russian Federation.
Collapse
Affiliation(s)
- T S Chekhlyaeva
- FSBI «Gabrichevsky research institute for epidemiology and microbiology» of the Surveillance of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
| | - D V Erokhov
- FSBI «Gabrichevsky research institute for epidemiology and microbiology» of the Surveillance of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
| | - I Yu Andrievskaya
- FSBI «Gabrichevsky research institute for epidemiology and microbiology» of the Surveillance of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
| | - P E Zherdeva
- FSBI «Gabrichevsky research institute for epidemiology and microbiology» of the Surveillance of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
| | - N T Tikhonova
- FSBI «Gabrichevsky research institute for epidemiology and microbiology» of the Surveillance of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
| |
Collapse
|
2
|
Okabayashi H, Komada K, Kidokoro M, Kitamura T, Miyano S, Ito T, Phounphenghak K, Pathammavong C, Murano K, Nagai M, Mori Y, Komase K, Xeuatvongsa A, Takeda M, Hachiya M. Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey. BMC Res Notes 2019; 12:155. [PMID: 30890154 PMCID: PMC6425695 DOI: 10.1186/s13104-019-4194-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 03/13/2019] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE Mumps-containing vaccine is currently not a component of the national immunization schedule in Lao People's Democratic Republic (PDR). Mumps itself is not a notifiable disease in the country and the seroprevalence of anti-mumps immunoglobulin G (IgG) in the general population is unknown. In this study, anti-mumps IgG was measured in 2058 blood samples to evaluate population immunity in the country. RESULTS The seroprevalence of anti-mumps IgG showed a gradual increase with increasing age, starting at 10.6% (95% CI 7.4-13.7) in participants aged 1-2 years, and almost plateaued at about 75% in individuals older than 11-12 years, though it still tended toward a small increase up to 89.6% (95% CI 86.6-92.6) in participants aged 40 years or older. Compared with the results of previous studies, this increase with increasing age is less marked and the plateau of anti-mumps seroprevalence is lower. We attribute this result mainly to the lower population density in Lao PDR.
Collapse
Affiliation(s)
- Hironori Okabayashi
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
| | - Kenichi Komada
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Minoru Kidokoro
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Tomomi Kitamura
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Shinsuke Miyano
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Tomoo Ito
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | | | | | - Keiko Murano
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Misato Nagai
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Yoshio Mori
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Katsuhiro Komase
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Anonh Xeuatvongsa
- National Immunization Program, Ministry of Health, Simuang, Vientiane, Lao PDR
| | - Makoto Takeda
- Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
| | - Masahiko Hachiya
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| |
Collapse
|